San Diego’s Regulus Therapeutics plans to raise $57.5 million in an IPO that takes advantage of incentives for emerging growth companies provided under the Jump Start Our Business Startups (JOBS) Act passed earlier this year.
In its IPO filing, the preclinical biopharmaceutical says it plans to follow reduced IPO disclosure and financial reporting requirements for five years, or until Regulus no longer qualifies as an emerging growth company. The company says it intend to use proceeds of the offering and a concurrent private placement to advance development of its microRNA drug candidates, capital expenditures, working capital, and other corporate purposes.
The company specializes in RNA interference, or RNAi technology, that uses snippets of ribonucleic acid, or microRNAs to block key signaling pathways linked to many diseases. The lead experimental compounds at Regulus are targeting four areas—cancer, hepatitis C, cardiovascular disease, and fibrotic disorders.
“We believe we have assembled the leading position in the microRNA field, including expertise in microRNA biology and oligonucleotide chemistry, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development processes,” the company says in its filing.
Regulus was founded in … Next Page »